Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Systemic and intraperitoneal inflammation are characteristic features of patients with end-stage renal disease undergoing chronic peritoneal dialysis (PD). Arginine vasopressin (AVP) and its surrogate marker copeptin play important roles in many pathophysiological processes in chronic kidney disease. The aim of this study was to assess if copeptin concentrations in plasma and dialysate were related to peritoneal transport parameters and residual renal function (RRF) in incident PD patients.
In 37 clinically stable incident PD patients (mean age 50 years, 68% women, 32% diabetes), a 4 h peritoneal equilibration test (PET) was performed 4–6 weeks after the onset of PD. Plasma (at 2 h of PET) and dialysate (at 4 h) concentrations of copeptin, high-sensitivity C-reactive protein and interleukin-6 (IL-6) were determined.
Plasma (80.7 ± 37.3 pg/mL) and dialysate (33.2 ± 18.0 pg/mL) concentrations of copeptin were correlated (Rs = 0.52, p = 0.001). Plasma and dialysate copeptin concentrations were negatively correlated with renal function as assessed by renal Kt/V (Rs = − 0.38; p = 0.021 and Rs = − 0.33; p = 0.047, respectively). At PET, dialysate copeptin negatively correlated with D/P creatinine (Rs = − 0.35, p = 0.033), and positively with D/D0 glucose (Rs = 0.33, p = 0.045) and ultrafiltration (Rs = 0.37, p = 0.024). Multivariate analysis showed that low dialysate copeptin (β = –0.30, p = 0.049) and high dialysate IL-6 (β = + 0.40, p = 0.012) were independent determinants of higher D/P creatinine.
Dialysate copeptin was negatively associated with D/P creatinine in incident PD patients suggesting a potential influence of copeptin or AVP on peritoneal solute transport rate that might involve vasoactive mechanisms.
Blake PG (2001) Integrated end-stage renal disease care: the role of peritoneal dialysis. Nephrol Dial Transpl 16(Suppl 5):61–66 CrossRef
Martikainen TA et al (2005) Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 25(5):453–460 PubMed
Enhörning S, Christensson A, Melander O (2019) Plasma copeptin as a predictor of kidney disease. Nephrol Dial Transpl 34(1):74–82 CrossRef
Bhandari SS et al (2009) Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116(3):257–263 CrossRef
Zittema D et al (2017) Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients. Nephrol Dial Transpl 32(suppl_1):146–153
Boertien WE et al (2012) Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transpl 27(11):4131–4137 CrossRef
Pecoits-Filho R et al (2006) Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 26(1):53–63 PubMed
Oh KH et al (2010) Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transpl 25(5):1639–1646 CrossRef
Zakaria ER et al (2008) Vasoactive components of dialysis solution. Perit Dial Int 28(3):283–295 PubMedCentral
- Dialysate copeptin and peritoneal transport in incident peritoneal dialysis patients
Anna Maria Muraszko
- Springer Netherlands
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II